INVESTIGADORES
ZAMPINI Renato
congresos y reuniones científicas
Título:
WORKING AT THE INTERFACE OF BIOPHYSICS AND IMMUNOLOGY WITH STRATEGIC APPLICATIONS OF THE S-RBD FROM SARS-COV-2
Autor/es:
TOMAS GRAU, RODRIGO; PLOPER, DIEGO; AVILA, CESAR; STAGNETTO, A; GONZÁLEZ LIZARRAGA, F; SOCIAS, BENJAMIN; CAZORLA, SILVIA; MALDONADO GALDEANO, CAROLINA; PERDIGÓN, GABRIELA; APICHELA, SILVANA A.; ARGAÑARAZ, MARTIN E.; ZAMPINI, RENATO; VELEZ, EVA; CHAVES, S; VERA PINGUITORE, ESTEBAN; LLAPUR, CONRADO; APFELBAUM, GABRIELA; AGUILAR LOPEZ, M.; ASNAR, P.; FLORES, I.; TOLEDO, R.; COSTA, D.; CHEIN, ROSANA
Reunión:
Jornada; Primeras jornadas virtuales de la Sociedad Argentina de Biofísica; 2020
Institución organizadora:
Sociedad Argentina de Biofísica
Resumen:
COVID-19, the pandemic caused by the SARS-CoV-2 virus, threatens to collapsehealthcare systems around the world. Therefore, the search for strategies capable ofcounteracting the effects of this disease is crucial. Taking into account that the receptorbinding domain (S-RBD), located in the glycoprotein S of the virus surface is crucial forits pathogenesis, and its region is a critical target for neutralizing antibodies, we set outto express and purify the recombinant S-RBD protein from SARS-CoV-2 and use it for thedevelopment of local diagnostic methods and research purposes. To obtain the S-RBDprotein, we generated a stable cell line by transducing HEK293T cells using a lentivirussystem. The correct transduction and expression were assessed by animmunofluorescence. S-RBD was purified by FPLC by affinity purification for itsubsequent use in: i) the development of an ELISA test ii) immunization of a llama toobtain nanoantibodies and iii) studying the potential effect of SARS-CoV-2 inneurodegenerative diseases. The continuous production of S-RBD protein was used forthe development of a reproducible, low cost, sensitive and robust serological test thatcorrelates with neutralizing antibodies. We found that 25% of patients tested withdetectable IgG anti-RBD have a high enough antibody titer (above 1/1000) to beconsidered as plasma donors. In llama, the titers obtained were above 1/80000, suitableto continue the project to purify nanoantibodies. The continuous production of S-RBDprotein also ensure enough reagent to study how SARS-CoV-2 might affectneurodegeneration from a biochemical and cell biology perspective.